CROI 2015 Program and Abstracts

Poster Sessions

POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in the Poster Hall from 2:30 PM to 4:00 PM on the scheduled day. A: Virology P-A1: Cellular Innate Immunity: Tuesday, 2/24/2015 P-A2: Nucleus Entry, Integration, and Export: Wednesday, 2/25/2015 P-A3: SAMHD1: Tuesday, 2/24/2015 P-A4: Enhancers and Inhibitors of Viral Infectivity and Entry: Thursday, 2/26/2015 P-A5: Envelopes, Receptors, and Tropism: Wednesday, 2/25/2015 P-A6: Nef Functions: Thursday, 2/26/2015 B: Molecular Epidemiology and HIV/SIV Evolution P-B1: Viral Origins and Recombinant Forms: Thursday, 2/26/2015 P-B2: Defining Epidemiologically Linked Transmission: Tuesday, 2/24/2015 P-B3: Transmission Clusters: Wednesday, 2/25/2015 P-B4: Transmission Networks: MSM: Tuesday, 2/24/2015 P-B5: Next Generation of Next-Generation Sequencing: Thursday, 2/26/2015 C: Pathogenesis—Human Studies and Animal Models P-C1: The Gut Microbiome: Tuesday, 2/24/2015 P-C2: The Mucosa in HIV/SIV Pathogenesis: Tuesday, 2/24/2015 P-C3: Innate and Unconventional T-Cell Responses: Wednesday, 2/25/2015 P-C4: Monocytes, Dendritic Cells, and Neutrophils: Wednesday, 2/25/2015 P-C5: Studies of HIV-Exposed Uninfected Individuals: Tuesday, 2/24/2015 P-C6: Host Factors in HIV Pathogenesis: Tuesday, 2/24/2015 P-C7: HIV/CMV Interactions in Transmission and Pathogenesis: Thursday, 2/26/2015 P-C8: Aging and Immune Senescence: Thursday, 2/26/2015 P-C9: Immune Pathogenesis of IRIS: Thursday, 2/26/2015 P-C10: Immune Activation and HIV Pathogenesis: Wednesday, 2/25/2015 P-C11: Manipulating Immune Activation: Wednesday, 2/25/2015 P-C12: Pathogenesis in Lymph Nodes: Thursday, 2/26/2015 P-C13: Dissecting Pathogenesis Through In Vitro Studies: Thursday, 2/26/2015 P-C14: Dissecting Pathogenesis Through In Vivo Studies: Thursday, 2/26/2015 E: Host Immune Responses to Infection, Vaccines, and Immunotherapy P-E1: The Effect of HIV Infection on B Cells: Tuesday, 2/24/2015 P-E2: The Envelope/Antibody Dynamic: Tuesday, 2/24/2015 P-E3: New Approaches to Immunostimulation: Wednesday, 2/25/2015 P-E4: Cellular Immune Response to HIV: Thursday, 2/26/2015 F: HIV Persistence, Reservoirs, Latency, Eradication, including Gene Therapy

P-G6: Inflammation and Markers of Brain Injury in HAND: Thursday, 2/26/2015 P-G7: Aging and Cognitive Decline: Wednesday, 2/25/2015 P-G8: Mitochondrial Dysfunction in HAND and Depression: Thursday, 2/26/2015 P-G9: Neuropathogenesis Mechanisms: Thursday, 2/26/2015 H: Clinical Pharmacology P-H1: Pharmacokinetics, Pharmacodynamics, and Adherence: Tuesday, 2/24/2015 P-H2: Pharmacogenomics: Tuesday, 2/24/2015 P-H3: Drug-Drug Interactions: Tuesday, 2/24/2015 P-H4: Pharmacokinetics in Compartments and Reservoirs and of Novel Formulations: Thursday, 2/26/2015 P-H5: NewTechnologies in Assessing Drug Interactions and Systemic and P-J1: ART: Recent Perspectives: Tuesday, 2/24/2015 K: Antiretroviral Therapy: Observational Studies P-K1: ART: Adherence, Adherence, Adherence: Tuesday, 2/24/2015 P-K2: ART: Monitoring and Biomarkers: Tuesday, 2/24/2015 P-K3: ART: Immunologic Response?The Good and The Bad: Wednesday, 2/25/2015 P-K4: ART: Mortality: Wednesday, 2/25/2015 L: HIV Drug Resistance P-L1: HIV Drug Resistance: Mechanisms and Mutations: Thursday, 2/26/2015 P-L2: HIV Subtypes and Resistance: Thursday, 2/26/2015 P-L3: Transmitted HIV Drug Resistance: Assessing the Threat: Thursday, 2/26/2015 P-L4: HIV Drug Resistance: Global Perspective and Clinical Implications: Thursday, 2/26/2015 M: HIV Diagnostics P-M1: Nucleic-Acid–Based Detection of HIV: Tuesday, 2/24/2015 P-M2: Comparison of HIV Incidence Assays: Wednesday, 2/25/2015 P-M3: HIV Detection, Tropism, and CD4 Measurement: Wednesday, 2/25/2015 N: Hepatitis Viruses P-N1: Natural History and Prognosis of HCV Infection: Tuesday, 2/24/2015 P-N2: HCV Therapy: Observations From Cohort Studies: Tuesday, 2/24/2015 P-N3: Treatment of HCV with DAAs: Short-Term Costs and Long-Term Benefits: Tuesday, 2/24/2015 P-N4: HCV: Getting the Drugs to ThoseWho Need Them: Tuesday, 2/24/2015 P-N5: HCV: Epidemiology and Case Detection: Wednesday, 2/25/2015 P-N6: Acute HCV Infection: Wednesday, 2/25/2015 P-N7: Immunopathogenesis of HCV Infection: Wednesday, 2/25/2015 P-N8: HCV Therapeutics: Preclinical Observations and Clinical Trials of DAAs: Thursday, 2/26/2015 P-N9: Mental Health and Treatment Adherence with Direct-Acting Antivirals: Thursday, 2/26/2015 P-N10: HCV: Resistance to Antiviral Agents: Thursday, 2/26/2015 P-N11: Other Hepatitis Viruses: HBV, HDV, HEV: Thursday, 2/26/2015 Intracellular Pharmacology: Thursday, 2/26/2015 I: Antiretroviral Therapy: Preclinical Studies P-I1: Drug Development: Wednesday, 2/25/2015 J: Antiretroviral Therapy: Randomized Clinical Trials

Poster Sessions

P-F1: Immune-Based Strategies in Latency: Tuesday, 2/24/2015 P-F2: Viral Reservoir Dynamics During ART: Thursday, 2/26/2015 P-F3: Cellular Factors of Latency: Thursday, 2/26/2015 P-F4: Dynamics of Latency and Reactivation: Wednesday, 2/25/2015 P-F5: Gene Editing: Wednesday, 2/25/2015 P-F6: HDAC Inhibitors: Tuesday, 2/24/2015 P-F7: Pharmacologic Latency-Reactivation Agents: Tuesday, 2/24/2015

P-F8: Latency Models and Assays: Wednesday, 2/25/2015 P-F9: Stem Cell Transplantation: Wednesday, 2/25/2015 G: Neuropathogenesis P-G1: CNS Reservoirs: Tuesday, 2/24/2015

P-G2: Optimizing ART for HAND Treatment and Prevention: Tuesday, 2/24/2015 P-G3: Neurologic Disorders in Resource-Limited Settings: Wednesday, 2/25/2015 P-G4: HAND Genetics: Thursday, 2/26/2015 P-G5: HAND Diagnosis and Predictors: Tuesday, 2/24/2015

22

CROI 2015